Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 21, 2024
Deals
Deal report: Astellas taps Kelonia for CAR Ts, Aurinia fails to find buyer, and more
Plus: Xoma-Kinnate, Almirall-Novo, Intellia-ReCode, Roche-Repare and more
BioCentury | Jun 2, 2022
Deals
June 1 Quick Takes: Repare gets $125M in Roche deal for precision oncology candidate
Plus J&J taps China-based biotech in ADC pact, and updates from Astellas-Go, Pfizer-GSK, Legend and more
BioCentury | Apr 22, 2022
Discovery & Translation
Genentech and Repare updates; plus an eye gland organoid and more
BioCentury’s roundup of translational news
BioCentury | Apr 14, 2022
Product Development
DDR combos on the horizon at AACR22
The first clinical data for a PARP1-selective inhibitor and deeper profiles of ATR-targeting agents suggest combinations will shape the field’s next act
BioCentury | Apr 9, 2022
Product Development
Synthetic lethality, protein degradation programs disappoint at AACR
C4, Zentalis and Repare are among the companies falling on AACR22 data
BioCentury | Mar 18, 2022
Finance
Impact lands runway to clear multiple synthetic lethality milestones
Shanghai company raises $61M series D1 with eyes on global deal for WEE1, IPO
BioCentury | Apr 21, 2021
Product Development
Synthetic lethality’s second wind
The thinking goes beyond the binary paradigm of target plus mutation
BioCentury | Feb 13, 2021
Product Development
Howdy partner: MD Anderson’s evolving industry collaboration strategy
How the cancer center is choosing clinical trial partners and advancing new modalities
BioCentury | Jun 20, 2020
Finance
Forma, Repare shine in first-day performances as biotech IPOs on NASDAQ maintain momentum
Beijing-based Genetron debuts with $1.4B valuation as quartet of biotechs price offerings
Items per page:
1 - 10 of 33